Topology-Controlled PEGylation of Elamipretide (SS31) Enhances Renal Accumulation and Protects Kidneys from Ischemia-Reperfusion Injury

Ischemia-reperfusion injury (IRI) remains a critical challenge in medicine, particularly as a leading cause of graft dysfunction following kidney transplantation and a major contributor to acute kidney injury (AKI). This damage is primarily driven by excessive mitochondrial oxidative stress and subsequent apoptotic cell death during the reperfusion phase. Elamipretide (SS31), a mitochondria-targeted tetrapeptide, has demonstrated robust renoprotective effects in preclinical models by mitigating mitochondrial dysfunction. However, its therapeutic potential is significantly limited by rapid renal elimination and insufficient pharmacokinetic exposure, necessitating strategies to improve its delivery and retention in the kidneys.

Researchers engineered novel multiarm PEG-SS31 conjugates with precisely controlled arm numbers and total PEG molecular weights. A key design feature was the incorporation of a ROS-cleavable thioketal linker, enabling the targeted release of SS31 specifically under conditions of oxidative stress. The team evaluated various PEG topologies, observing that the lead conjugate spontaneously self-assembled into stable nanoparticles. These optimized conjugates were then tested in a murine IRI model to assess their renal accumulation and therapeutic efficacy, comparing them against free SS31 and alternative PEGylation architectures. Primary endpoints included measurements of renal accumulation, tubular injury, and apoptotic markers.

The study identified a lead PEG-SS31 conjugate topology that exhibited significantly improved pharmacological properties. This specific architecture, which self-assembled into nanoparticles, produced markedly enhanced renal accumulation when compared to both free SS31 and other PEGylation designs. This improved targeting translated directly into superior therapeutic outcomes in the murine IRI model. The optimized PEG-SS31 conjugate demonstrated substantial renoprotection, evidenced by a significant reduction in key markers of kidney damage. Specifically, the treatment led to:

Reduced tubular injury and a decrease in apoptotic cell death within the renal tissue, indicating a direct protective effect against IRI-induced pathology. These findings underscore the critical role of PEG topology in dictating the in vivo performance of kidney-targeted peptide therapeutics, suggesting that precise structural control can overcome pharmacokinetic limitations of compounds like SS31.